Document Detail


Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate.
MedLine Citation:
PMID:  11157369     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Treatment of intradialytic hypotension (IDH) in the end-stage renal disease population has been a difficult task for nephrologists caring for these patients. The presence of multiple pathogenic factors contributes to hemodynamic instability and explains why therapies that modulate only a specific aspect of the problem are only partially effective. Cool dialysate (34.5 degrees C to 35.5 degrees C) and midodrine may provide hemodynamic stability through an increase in peripheral vascular resistance, whereas high dialysate calcium concentration (HDCa; 3.5 mEq/L) improves intradialytic blood pressure through preservation of cardiac output. Theoretically, the combination of these two types of therapies might further reduce the frequency and severity of hypotension during hemodialysis (HD). We undertook a study to evaluate the effect of HDCa added to midodrine and/or cool dialysate in the treatment of patients with severe IDH. Twenty-eight patients met the entry criteria, and 23 patients completed the prospective crossover study. Five patients dropped out of the study secondary to hypercalcemia. The addition of HDCa significantly improved post-HD mean arterial pressure (MAP; 95.6 +/- 12.7 versus 90.8 +/- 12.5 mm Hg; P = 0.002). The decreases in MAP from pre-HD to lowest intradialytic (16.3 +/- 8.2 versus 20.6 +/- 10.0 mm Hg; P = 0.009) and pre-HD to post-HD (2.0 +/- 8.5 versus 8.15 +/- 10.8 mm Hg; P = 0.002) were significantly reduced with HDCa compared with low dialysate calcium. However, there were no significant improvements in symptoms of or interventions for IDH. Thus, it appears that the addition of HDCa to midodrine and/or cool dialysate further improves blood pressure in patients with IDH. However, this therapy did not reduce symptoms or interventions required for IDH. In addition, hypercalcemia complicated this therapy in 22% of the patients.
Authors:
R Alappan; D Cruz; A K Abu-Alfa; R Mahnensmith; M A Perazella
Related Documents :
19397219 - Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a s...
11509799 - Risk factors for hypertension in chronic hemodialysis patients: baseline data from the ...
17474559 - Comparison of predilution hemodiafiltration and low-flux hemodialysis at temperature-co...
21769299 - Explicit control of implicit responses: simple directives can alter iat performance.
16772759 - Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients.
3799429 - Increasing daytime vascular resistance with progressive hypertension in ambulant patients.
975489 - The effect of a new anti-allergic drug ici 74, 9i7, given by aerosol, on nasal stenosis...
15072949 - Cardiac-specific norepinephrine mass transport and its relationship to left ventricular...
9572789 - Effects of chest wall vibration on breathlessness during hypercapnic ventilatory response.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  American journal of kidney diseases : the official journal of the National Kidney Foundation     Volume:  37     ISSN:  1523-6838     ISO Abbreviation:  Am. J. Kidney Dis.     Publication Date:  2001 Feb 
Date Detail:
Created Date:  2001-02-22     Completed Date:  2001-05-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8110075     Medline TA:  Am J Kidney Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  294-9     Citation Subset:  IM    
Affiliation:
Section of Nephrology, Yale University School of Medicine, New Haven, CT, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Pressure
Calcium* / analysis
Female
Hemodialysis Solutions / chemistry*
Humans
Hypotension / etiology,  therapy*
Kidney Failure, Chronic / therapy*
Male
Middle Aged
Midodrine / therapeutic use*
Renal Dialysis / adverse effects*
Temperature
Chemical
Reg. No./Substance:
0/Hemodialysis Solutions; 42794-76-3/Midodrine; 7440-70-2/Calcium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prokinetic agents increase plasma albumin in hypoalbuminemic chronic dialysis patients with delayed ...
Next Document:  Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia:...